EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA), Scientific Committee members and experts

Public declaration of interests

I, **Silvia Stacchiotti**

Organisation/Company: National Cancer Institute of Milan

Country: Italy

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
09/2014-09/2014	Glaxo	pazopanib	sarcoma
10/2018-10/2018	Bayer	Regorafenib, Larotrectinib	Sarcoma
05/2015-05/2015	Karyopharm	Selinexor	liposarcoma
03/2019-(current)	Maxivax	chordoma	
03/2018-03/2018	Epizyme	tazemetostat	sarcoma
12/2018-(current)	Bavarian Nordic	BRACHY-CHOR-001	chordoma
02/2016-12/2018	Lilly	olaratumab	soft tissue sarcoma
11/2018-11/2018	Intellisphere	CMB305	Synovial sarcoma
01/2016-(current)	Daiichi	pexidartinib	TGCT
06/2019-06/2019	Deciphera	DCC-3014	TGCT
12/2017-12/2017	Immunedesign	NY-ESO vaccine	Synovial sarcoma

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
10/2008-01/2019	Amgen	Denosumab	Advanced giant cell tumor of the bone
06/2011-05/2013	Novartis	Nilotinib	Advanced pigmented villonodular synovitis (PVNS)
09/2011-06/2012	Pharmamar	Eribulin	Soft tissue sarcoma
06/2011-10/2012	Infinity Pharmaceuticals	IPI-926	Advanced chondrosarcoma
01/2011-11/2016	Bayer	Regorafenib	Gastrointestinal stromal tumor (GIST)
04/2013-(current)	Pharmamar	Trabectedin	Well differentiated-dedifferentiated liposarcoma
01/2014-06/2015	Novartis	BYL719	GIST
01/2012-11/2012	Novartis	BKM120	GIST
02/2012-07/2014	Novartis	Dovitinib	GIST
01/2014-10/2014	Morphotek	MORAb-004	sarcoma
01/2012-12/2014	ImClone	IMC343	GIST
12/2015-(current)	Daiichi	PLX3397	Advanced pigmented villonodular synovitis (PVNS)
12/2015-(current)	Lilly	Olaratumab	Advanced soft tissue sarcoma
12/2015-(current)	Epyzime	Tazemetostat	Advanced soft tissue sarcoma
04/2018-09/2019	Lilly	olaratumab in combination with doxorubicine and ifosfamide	soft tissue sarcoma
03/2018-(current)	Advenchen	anlotinib	alveolar soft part sarcoma, synovial sarcoma, leiomyosarcoma
06/2017-(current)	Novartis	ceritinib	myofibroblastic inflammatory tumor
09/2018-(current)	Karyopharm	selinexor	liposarcoma
01/2018-(current)	Arog Pharmaceutical	Crenolanib	GIST

01/2019-(current)	Blueprint	avapritinib	GIST
08/2019-(current)	Deciphera	ripretinib	GIST
01/2020-(current)	SpringWorks	Nirogacestat	Desmoid fibromatosis

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Pharmamar	Grant

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

Academic trial:

"Phase 2 study of lapatinib in EGFR/HER2NEU positive advanced chordoma" (EudraCT number: 2009-014456-29), closed in 2012;
"Cross-tumoral phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET ("CREATE")" (EudraCT number 2011-001988-52), ongoing;
"GEIS-32: Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients with Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)" (EudraCT Number: 2013-005456-15), ongoing;
"Phase II study on imatinib in combination with RAD001 in advanced chordoma" (EudraCT number: 2010-021755-34), ongoing;
"A phase 2 study randomized non comparative on the activity of trabectedin or gemcitabine + docetaxel in metastatic or locally relapsed uterine leiomyosarcoma pretreated with conventional chemotherapy" (EudraCT number: 2009-016017-24), ongoing;
"Toremifene in desmoid tumor: prospective clinical trial and identification of potential molecular targets", ongoing;
"Phase 3 study of localized high-risk soft tissue sarcomas of the extremities and trunk wall in adults: an integrating approach comprising standard vs histotype-tailored neoadjuvant chemotherapy", ongoing;
"Phase II Study of Axitinib in Advanced Solitary Fibrous Tumor" (EudraCT number:2013-005596-40), ongoing.

"Phase II Study of Regorafenib in Advanced Solitary Fibrous Tumor (SOFT)", ongoing.
"Phase II Study of doxorubicin plus dacarbazine versus trabectdin (STRDA)", ongoing.
"Phase II Study of sunitinib plus nivolumab in advanced soft tissue sarcomas (IMMUNOSARC-52)", closed.
"Phase II Study of eribulin in Advanced Solitary Fibrous Tumor!, onging.
"Phase I Study of trabectedin plus olaparib in Advanced Sarcoma", closed.

Member of the EORTC bone and soft tissue sarcoma group
Member of the Italian Sarcoma Group
Member of Board of the Connective Tissue Oncology Society
Member of the Advisory board of the Chordoma Foundation Advocacy Group
Member of the Advisory board of the Desmoid Tumor Foundation

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with

any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Silvia Stacchiotti
Date:	2020-04-21

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template